Diagnostics groups dominated the health and bio news flow, with regulatory progress and commercial traction on show despite a soft session for share prices across the board. Cizzle Biotechnology secured a key US accreditation for its lung cancer test, CelLBxHealth reported a sharp narrowing of cash burn alongside doubling revenue, and EDX Medical landed a trio of employer contracts for its health screening service.
Cizzle wins US lab accreditation for lung cancer test
Cizzle Biotechnology Holdings (CIZ) gained accreditation in the United States for its lung cancer test, a milestone Executive Chairman Allan Syms described as coming in what he called "probably the most important period in Cizzle's development since the company was founded." The accreditation marks a step toward commercial deployment of the diagnostic in the US market, one of the largest addressable markets for early cancer detection. Shares slipped 6.977% to 2.0p despite the regulatory advance, reflecting a broader pullback across the sector rather than any read-through from the news itself.
CelLBxHealth halves cash burn as revenue doubles
CelLBxHealth (CLBX) cut its cash burn in half while doubling revenue in the second quarter, a combination that Executive Chairman Jan Groen pointed to as validation of the company's commercial reset. Groen said the growth was "an early sign of the successful implementation of our revised commercial strategy," language that signals management sees the improved trading as the start of a sustained trend rather than a one-off. The stock nonetheless fell 4.93% to 1.331p, with investors seemingly waiting for further evidence the improved metrics can be sustained before re-rating the shares.
EDX Medical lands three employer screening contracts
EDX Medical Group (EDX) signed three employers to a combined £2m health screening rollout, extending its push into workplace diagnostics. Professor Sir Chris Evans said "it is abundantly clear that early detection of a range of diseases can be transformative for both employee and employer," framing the contracts as proof of concept for a model the company hopes to scale across the corporate market. EDX shares eased 1.9% to 10.3p on the day, a modest move against a deal that broadens the group's revenue base beyond its core testing operations.
